LimmaTech Biologics
LimmaTech Biologics
Revolutionary Model Predicts Biologic Processing Variations
🔍 Scientists have developed a mathematical model to predict RTD in continuous manufacturing of biologics. 🔬🔬🧪💯🔬
MilliporeSigma’s €300 Million Investment Fuels South Korea’s Bioproduction Boom
📢 MilliporeSigma invests €300 million in South Korea bioproduction site, creating 300 jobs and supporting biotech and pharma industries. 🏭💼🧪🧬
Boosting Lyophilization Productivity by 300: A Game-Changing Digital Twin Approach
📰 Researchers at Clausthal University of Technology in Germany have found that using a digital twin approach during the freeze-drying process for biologics can increase productivity by up to 300 🚀💰. This approach also reduces costs by 74 💵 and lowers the global warming potential by 64 🌍. Lyophilization DigitalTwin
Swiss Vaccine Developer Wins $22m Grant to Tackle Global Gonorrhea Crisis
🔬 Swiss vaccine developer LimmaTech Biologics AG receives $2.2m grant from CARB-X to fight Neisseria gonorrheae. 💉
Powerhouse Partnership Forms Europe’s Top Biologics CDMO
🔬💪 Biovian and 3P Biopharmaceuticals team up to form 3PBIOVIAN, a pan-European biologics CDMO with full development and manufacturing capabilities.
Game-Changing Merger Creates European CDMO Powerhouse
🔍 Biovian and 3P Biopharmaceuticals merge to create 3PBIOVIAN, a European CDMO offering end-to-end services. 🌍👥🔬🧫🧬💪
Pharma’s Tech Revolution: AI and Synbio Supercharge Biologics
📰 Pharma is using new technologies like AI and synthetic biology to maximize biologics manufacturing. 💊 Innovations are improving antibody stability and yield, accelerating production and drug development. 🌐
LimmaTech Biologics Secures Exclusive Rights for Breakthrough Vaccine
🔬 LimmaTech Biologics secures license for AbVacc's LBT-SA7 vaccine! Exciting news in the fight against hospital-acquired infections. 💉✨🌍 biotech vaccine
